

Information and consent for the patient support program for specialty drugs

Please fill out this page only if you live outside Quebec.

INFORMATION

The prescription drug that is the object of your request is part of our patient support program. Designed to help you better manage your medical condition, this program provides you with many benefits such as access to professional support from a team of pharmacists. For more information, see the *Prior Authorization Drugs and the Patient Support Program* brochure, available at www.desjardinslifeinsurance.com/PAD.

If your contract includes the program, you may be required to participate.

A healthcare professional from the provider selected by Desjardins Insurance will contact you to let you know the status of your request, to explain how the program works and to direct you to a preferred pharmacy. That professional may also contact your attending physician to get any missing information. The information obtained as a result of this prior authorization request will be sent to the third party and used to process your request. This is why your signature is required.

IMPORTANT

As part of the patient support program, you will be reimbursed for your specialty drug only if you purchase it through the preferred pharmacy network.

CONSENT TO DISCLOSE TO A THIRD PARTY

For the sole purpose of the patient support program, I authorize Desjardins Insurance to disclose to the third party personal information about me, especially my medical information, that is needed for the program. I understand that the third party may share this information with my doctors, pharmacists and other healthcare professionals as part of this program.

This consent also applies to the disclosure of personal information concerning my dependents, insofar as this request involves them.

Last name and first name of the member (PLEASE PRINT)	Contract No.	Certificate No.				
Email address of the member						
Signature of the member		Date				
Last name and first name of the parent or legal guardian (if necessary)						
Signature of the parent or legal guardian (if necessary)		Date				

This consent is an integral part of the attached Prior Authorization Request form.



C. P. 3950 Lévis (Québec) G6V 8C6 <u>desjardinslifeinsurance.com/planmember</u> 1-844-410-6485

PRIOR AUTHORIZATION REQUEST

GLATECT (GLATIRAMER ACETATE)

PLEASE READ THE INSTRUCTIONS ON THE LAST PAGE OF THIS FORM.

	PATIENT IDENTIFICATION	NT IDENTIFICATION – To be completed by the member.							
	Patient's last and first name			Relations	ship with r	member		Patient's da	te of birth
				Memb	oer 🗆	Spouse	Dependent child		טט וייוייו
	Member's last and first nam	e		1	Coi	ntract No.		Certificate No.	
	No., street, apt.		City					Province	Postal code
	Telephone Nos – Home:	Office:		Ext	tension:		Email:		
	_	equest includes confidential inform	•	-		to be inform	ed of the decision:		
	☐ By mail (The response to	your request will be sent to the a	ddress indicated in th	nis section.)		☐ By fax:			
	Coordination of benefits:	If the patient has coverage under	r a private insurance	plan or is e	nrolled in	a provincia	l drug insurance pla	an, please subm	it the request to this
		copy of the decision notice and th							·
		Does the patient have drug cov	erage under a private	insurance p	olan?	_			
	DDU/475 DI 441	Yes – Please provide a copy	of the notice of appro	oval or refus	al. \rightarrow	Сору а	ttached to this forn	n.	
	PRIVATE PLAN	Specify: Name of the insurer: _			Co	ontract No.:		_ Certificate No.	:
		No							
		Has a request for reimburseme	nt been submitted ur	nder your pr	ovincial p	lan?			
	PROVINCIAL PLAN	Yes – Please provide a copy	of the notice of appro	oval or refus	al. \rightarrow	Сору а	ttached to this form	n.	
		No – Please explain:				.,			
		Is the patient enrolled in a pati	ent support program?	? Yes	No				
	PATIENT SUPPORT								
	PROGRAM	If so – Program name:						_	
4		Contact person:				Telephone			extension:
1		THORIZATION FOR THE COL							
	•	provided on the claim form is ac	•		•		,		•
		rposes of managing my file and secessary to manage my file. The nor	,	•		_			
		b) communicate to the said person							·
	when necessary use the pers	sonal information it may have abou	ut me in existing files t	that are now	closed. T	his authoriza	ation is also valid for	the collection, u	
	of personal information con	cerning my dependents, insofar as	applicable to the cla	im. A photo	copy of th	is authorizat	tion is as valid as the	e original.	
	Signature of member: Date:								
	Last name and first name of	f parent/legal guardian (if applica	hla).						
			biej.						
		ent/legal guardian (if applicable):					Date:		
2		MUNICATION OF PERSONAL							
		im more efficiently, do you author the reasons for the decision on yo	•		orm the p	atient suppo	ort program and the	e attending phy	sician or the attending
	physician's medical team of the reasons for the decision on your prior authorization request?								
	Signature of member:	YesNo nature of member: Date:							
		lature of member.							
	ast name and first name of parent/legal guardian (if applicable):								
	ignature of patient or parent/legal guardian (if applicable): Date:								
	ATTENDING PHYSICIAN	ENDING PHYSICIAN SECTION – To be completed by the attending physician.							
	Physician's last and first name (PLEASE PRINT) License No. Specialty								
No standard to									
No., street, suite City Province					Province	Postal code			
	Telephone No.:								
>	Signature of physician:								
Drug name Formulation Strength Dosage Scheduled duration of treatment					ent				
Where is the drug administered?					t				
	Other (please specify):								
	Other (piease specify).								

C ATTENDING PHYSICIAN SECTION – Continued

- Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member.
- In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context.

Diagnosis		
First acute clinical demyelinating event Relapsi	ng-remitting multiple sclerosis	
Other therapeutic indication(s) – Please specify:		
Information relating to first acute clinical episode of dem		
Presence of at least one asymptomatic hyperintense lesion	on T2 in the following regions: Periventricular Juxtacortical	☐ Infratentorial ☐ Spinal cord
Diameter of the largest region:	Expanded Disability Status Scale (EDSS) score:	
Information relating to remitting multiple sclerosis		
How many clinical relapses has the patient experienced? $_$		
Dates at which the two last relapses occured:		
Expanded Disability Status Scale (EDSS) score:		
PRIOR MEDICATION OR TREATMENT Has the patient ever used medication or received treatmen If not, please explain:	nt for this medical condition?	
If so, please list any medication already used or any treatm	ent already received for this medical condition:	
MEDICATION OR TREATMENT NAME	OUTCOME	TREATMENT PERIOD
Name:	Inefficiency Intolerance Contraindication	From:
Dose:	Specify:	To:
Name:	Inefficiency Intolerance Contraindication	From:
Dose:	Specify:	To:
Name:	Inefficiency Intolerance Contraindication	From:
Dose:	Specify:	To:
Name:	Inefficiency Intolerance Contraindication	From:
Dose:	Specify:	To:
Is the patient severely intolerant or is there a contra-indica Interferon beta Teriflunomide Nataliz	_	
PRESCRIPTION RENEWAL		
Number of clinical relapses in the past year:		
Expanded Disability Status Scale (EDSS) score:		

D INSTRUCTIONS - HOW TO COMPLETE AND RETURN THIS FORM

- 1. Complete sections A and B.
- 2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.
- 3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.

4. Send form: by fax: Designations Insurance by mail: Designations Insurance

Group Insurance, Health Claims,
418-838-2134 or 1-877-838-2134 (toll-free)
Group Insurance, Health Claims
C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.